Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update

Dow Jones2025-07-09

By Adriano Marchese

Hims & Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell Novo Nordisk's branded version.

The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide.

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing.

The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices.

The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy to Hims & Hers patients.

The pharmaceutical giant had also said in June that it had concerns about the safety of knockoff versions of Wegovy, and that Hims & Hers' deceptive marketing of such knockoffs put patient safety at risk.

Hims & Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 09, 2025 10:10 ET (14:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2550655658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550655658","market":"hk","top_or_hot":-1,"title":"Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s branded version. \n</p>\n<p>\n  The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide. \n</p>\n<p>\n  The move follows a dramatic breakup in June between Hims &amp; Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims &amp; Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing. \n</p>\n<p>\n  The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices. \n</p>\n<p>\n  The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy to Hims &amp; Hers patients. \n</p>\n<p>\n  The pharmaceutical giant had also said in June that it had concerns about the safety of knockoff versions of Wegovy, and that Hims &amp; Hers' deceptive marketing of such knockoffs put patient safety at risk. \n</p>\n<p>\n  Hims &amp; Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 10:10 ET (14:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 22:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s branded version. \n</p>\n<p>\n  The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide. \n</p>\n<p>\n  The move follows a dramatic breakup in June between Hims &amp; Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims &amp; Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing. \n</p>\n<p>\n  The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices. \n</p>\n<p>\n  The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy to Hims &amp; Hers patients. \n</p>\n<p>\n  The pharmaceutical giant had also said in June that it had concerns about the safety of knockoff versions of Wegovy, and that Hims &amp; Hers' deceptive marketing of such knockoffs put patient safety at risk. \n</p>\n<p>\n  Hims &amp; Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 10:10 ET (14:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550655658","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550655658","pubTimestamp":1752070200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell Novo Nordisk's branded version.The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide.The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing.The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices.The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务"},"translate_title":"Wegovy影响后，Hims&Hers Times转向加拿大仿制药减肥药——更新","themeId":"f617459ce2719dfa6414ce4f200b8463","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Hims & Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell Novo Nordisk's branded version. \n\n\n  The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide. \n\n\n  The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing. \n\n\n  The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices. \n\n\n  The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy to Hims & Hers patients. \n\n\n  The pharmaceutical giant had also said in June that it had concerns about the safety of knockoff versions of Wegovy, and that Hims & Hers' deceptive marketing of such knockoffs put patient safety at risk. \n\n\n  Hims & Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 10:10 ET (14:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550655658","isCrawlerRequest":true}